Licensing to remain a key part of strategy, Japanese firms say
This article was originally published in Scrip
As in-house drug development becomes increasingly complex and costly, at least two major Japanese companies expect licensing and external alliances to become an ever more important component of their R&D effort.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.